ImmunomeInc Cash vs Long Term Debt Analysis
IMNM Stock | USD 14.94 0.23 1.56% |
ImmunomeInc financial indicator trend analysis is infinitely more than just investigating ImmunomeInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmunomeInc is a good investment. Please check the relationship between ImmunomeInc Cash and its Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.
Cash vs Long Term Debt
Cash vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmunomeInc Cash account and Long Term Debt. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between ImmunomeInc's Cash and Long Term Debt is -0.69. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of ImmunomeInc, assuming nothing else is changed. The correlation between historical values of ImmunomeInc's Cash and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of ImmunomeInc are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Cash i.e., ImmunomeInc's Cash and Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.69 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Cash
Cash refers to the most liquid asset of ImmunomeInc, which is listed under current asset account on ImmunomeInc balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from ImmunomeInc customers. The amounts must be unrestricted with restricted cash listed in a different ImmunomeInc account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Long Term Debt
Long-term debt is a debt that ImmunomeInc has held for over one year. Long-term debt appears on ImmunomeInc balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on ImmunomeInc balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from ImmunomeInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunomeInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.At this time, ImmunomeInc's Selling General Administrative is very stable compared to the past year. As of the 2nd of June 2024, Enterprise Value is likely to grow to about 121.1 M, while Issuance Of Capital Stock is likely to drop about 29.1 K.
2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 503K | 728K | 689.9K | Interest Income | 5K | 2.7M | 2.9M |
ImmunomeInc fundamental ratios Correlations
Click cells to compare fundamentals
ImmunomeInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmunomeInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 5.1M | 44.5M | 57.9M | 24.0M | 148.5M | 156.0M | |
Short Long Term Debt Total | 564K | 613K | 317K | 293K | 1.7M | 845.7K | |
Other Current Liab | 666K | 1.4M | 6.7M | 4.6M | 7.7M | 3.9M | |
Total Current Liabilities | 1.7M | 3.0M | 9.7M | 7.3M | 21.8M | 22.9M | |
Total Stockholder Equity | (35.6M) | 41.3M | 48.2M | 16.7M | 119.9M | 125.9M | |
Net Tangible Assets | (35.6M) | 41.3M | 48.2M | 16.7M | 19.2M | 10.0M | |
Property Plant And Equipment Net | 1.7M | 1.5M | 855K | 965K | 3.6M | 2.0M | |
Net Debt | (2.0M) | (39.2M) | (48.9M) | (20.0M) | (97.0M) | (92.2M) | |
Retained Earnings | (36.6M) | (54.4M) | (79.1M) | (116.0M) | (222.8M) | (211.7M) | |
Accounts Payable | 548K | 1.2M | 3.1M | 2.4M | 3.3M | 2.0M | |
Cash | 2.5M | 39.8M | 49.2M | 20.3M | 98.7M | 103.6M | |
Non Current Assets Total | 1.9M | 1.6M | 1.3M | 1.4M | 3.8M | 2.3M | |
Cash And Short Term Investments | 2.5M | 39.8M | 49.2M | 20.3M | 138.1M | 145.0M | |
Common Stock Shares Outstanding | 5.7M | 3.4M | 11.5M | 12.1M | 19.8M | 10.5M | |
Liabilities And Stockholders Equity | 5.1M | 44.5M | 57.9M | 24.0M | 148.5M | 156.0M | |
Non Current Liabilities Total | 39.0M | 142K | 12K | 62K | 6.8M | 9.9M | |
Capital Lease Obligations | 239K | 0.0 | 317K | 293K | 1.7M | 1.7M | |
Other Current Assets | 579K | 3.1M | 7.4M | 2.3M | 6.3M | 3.7M | |
Other Stockholder Equity | 927K | 95.7M | 127.3M | 132.7M | 342.7M | 359.8M | |
Total Liab | 40.7M | 3.2M | 9.7M | 7.4M | 28.7M | 15.9M | |
Net Invested Capital | (35.3M) | 42.0M | 48.2M | 16.7M | 119.9M | 125.9M | |
Property Plant And Equipment Gross | 1.7M | 1.5M | 3.9M | 681K | 7.5M | 7.9M | |
Total Current Assets | 3.1M | 42.9M | 56.6M | 22.6M | 144.7M | 151.9M | |
Accumulated Other Comprehensive Income | (38.9M) | (44.5M) | (57.9M) | 0.0 | 22K | 23.1K | |
Net Working Capital | 1.5M | 39.9M | 46.9M | 15.3M | 122.9M | 129.0M | |
Short Term Debt | 451K | 479K | 317K | 293K | 310K | 328.3K | |
Property Plant Equipment | 1.7M | 1.5M | 855K | 681K | 612.9K | 1.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as ImmunomeInc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for ImmunomeInc Stock analysis
When running ImmunomeInc's price analysis, check to measure ImmunomeInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunomeInc is operating at the current time. Most of ImmunomeInc's value examination focuses on studying past and present price action to predict the probability of ImmunomeInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunomeInc's price. Additionally, you may evaluate how the addition of ImmunomeInc to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is ImmunomeInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunomeInc. If investors know ImmunomeInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunomeInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.58) | Revenue Per Share 0.427 | Quarterly Revenue Growth (0.56) | Return On Assets (0.15) | Return On Equity (1.55) |
The market value of ImmunomeInc is measured differently than its book value, which is the value of ImmunomeInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunomeInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunomeInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunomeInc's market value can be influenced by many factors that don't directly affect ImmunomeInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunomeInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunomeInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunomeInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.